gavo-cel
Generic: gavocabtagene autoleucel·Code: TC-210
gavo-cel: developed by 1 company · 1 clinical trial tracked.
gavo-cel evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect gavo-cel to TCRR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could gavo-cel → TCRR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| TCR2 THERAPEUTICS INC. (TCRR) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Primary endpoint: Phase 1- Primary Objective
InterventionalRandomizedopen57 targetStarted 2019-04Completion 2028-1111 sites · Canada, United StatesTCR2 Therapeutics
Frequently asked questions
Who is developing gavo-cel?
gavo-cel is being developed by TCR2 THERAPEUTICS INC..
How many clinical trials involve gavo-cel?
BioSniper tracks 1 clinical trial involving gavo-cel.